REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
Go back to REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 6.66 +0.38 (6.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.28 | 52 Week High | $25.00 | |||
| Open | $6.36 | 52 Week Low | $7.07 | |||
| Day High | $6.67 | P/E | N/A | |||
| Day Low | $6.32 | EPS | $0.00 | |||
| Volume | 904,546 | |||||
